Denali Advisors LLC Has $3.59 Million Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Denali Advisors LLC raised its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 102.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 104,314 shares of the company's stock after buying an additional 52,814 shares during the quarter. Denali Advisors LLC owned about 0.18% of Harmony Biosciences worth $3,589,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of HRMY. GAMMA Investing LLC grew its position in shares of Harmony Biosciences by 92.6% during the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company's stock worth $31,000 after buying an additional 436 shares during the period. Mendota Financial Group LLC lifted its stake in Harmony Biosciences by 24,125.0% in the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company's stock valued at $33,000 after acquiring an additional 965 shares in the last quarter. KBC Group NV lifted its stake in Harmony Biosciences by 79.9% in the 4th quarter. KBC Group NV now owns 1,844 shares of the company's stock valued at $63,000 after acquiring an additional 819 shares in the last quarter. Quantbot Technologies LP bought a new stake in Harmony Biosciences in the 3rd quarter valued at approximately $74,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Harmony Biosciences by 21.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company's stock valued at $80,000 after acquiring an additional 360 shares in the last quarter. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Harmony Biosciences Stock Performance

Shares of HRMY stock traded up $1.10 during trading on Friday, reaching $33.85. 1,033,155 shares of the company's stock were exchanged, compared to its average volume of 641,963. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $1.94 billion, a PE ratio of 16.04, a PEG ratio of 0.47 and a beta of 0.80. Harmony Biosciences Holdings, Inc. has a twelve month low of $28.14 and a twelve month high of $41.61. The firm's fifty day moving average price is $36.63 and its 200-day moving average price is $35.79.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.11. The business had revenue of $201.30 million for the quarter, compared to analyst estimates of $201.25 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The firm's revenue was up 19.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.45 EPS. As a group, sell-side analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Insider Buying and Selling

In other Harmony Biosciences news, CEO Jeffrey M. Dayno sold 19,293 shares of the company's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $40.13, for a total value of $774,228.09. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Sandip Kapadia sold 25,000 shares of the company's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.18, for a total value of $1,004,500.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 72,452 shares of company stock valued at $2,831,679. 30.80% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on HRMY shares. Needham & Company LLC restated a "buy" rating and issued a $50.00 target price on shares of Harmony Biosciences in a research note on Tuesday. Mizuho cut their target price on Harmony Biosciences from $52.00 to $42.00 and set an "outperform" rating on the stock in a research note on Thursday, February 20th. HC Wainwright dropped their price objective on Harmony Biosciences from $75.00 to $70.00 and set a "buy" rating on the stock in a research note on Thursday. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a research note on Tuesday, February 11th. They set a "buy" rating and a $55.00 price objective on the stock. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $53.11.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.